These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37670043

  • 21. Treatment and Coronary Artery Aneurysm Formation in Kawasaki Disease: A Per-Day Risk Analysis.
    van Stijn D, Korbee JM, Netea SA, de Winter VC, Zwinderman KAH, Kuipers IM, Kuijpers TW.
    J Pediatr; 2022 Apr; 243():167-172.e1. PubMed ID: 34968497
    [Abstract] [Full Text] [Related]

  • 22. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
    J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
    [Abstract] [Full Text] [Related]

  • 23. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 24. Risk scores for Kawasaki disease, a management tool developed by the KAWA-RACE cohort.
    Grasa CD, Fernández-Cooke E, Domínguez-Rodríguez S, Aracil-Santos J, Barrios Tascon A, Sánchez-Manubens J, Mercader B, Antón J, Nuñez E, Villalobos E, Bustillo M, Camacho M, Oltra Benavent M, Giralt G, Bello Naranjo AM, Rocandio B, Calvo C, Spanish group for the study of Kawasaki Disease (KAWA-RACE).
    Clin Rheumatol; 2022 Dec 26; 41(12):3759-3768. PubMed ID: 35939163
    [Abstract] [Full Text] [Related]

  • 25. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW.
    Arch Dis Child; 2021 Mar 26; 106(3):247-252. PubMed ID: 32943389
    [Abstract] [Full Text] [Related]

  • 26. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA.
    Arch Dis Child; 2015 Apr 26; 100(4):366-8. PubMed ID: 25670405
    [Abstract] [Full Text] [Related]

  • 27. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
    Clin Exp Med; 2019 May 26; 19(2):173-181. PubMed ID: 30617865
    [Abstract] [Full Text] [Related]

  • 28. The Harada score in the US population of children with Kawasaki disease.
    Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J.
    Hosp Pediatr; 2014 Jul 26; 4(4):233-8. PubMed ID: 24986993
    [Abstract] [Full Text] [Related]

  • 29. Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease.
    Masuda H, Ae R, Koshimizu TA, Matsumura M, Kosami K, Hayashida K, Makino N, Matsubara Y, Sasahara T, Nakamura Y.
    Pediatr Cardiol; 2021 Apr 26; 42(4):969-977. PubMed ID: 33682062
    [Abstract] [Full Text] [Related]

  • 30. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M, Shiozawa Y, Kagawa J.
    Pediatr Cardiol; 2015 Aug 26; 36(6):1159-65. PubMed ID: 25753685
    [Abstract] [Full Text] [Related]

  • 31. Usefulness of Kawasaki disease risk scoring systems to the Turkish population.
    Öztarhan K, Varlı YZ, Aktay Ayaz N.
    Anatol J Cardiol; 2020 Aug 26; 24(2):97-106. PubMed ID: 32749248
    [Abstract] [Full Text] [Related]

  • 32. Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease.
    Fabi M, Andreozzi L, Frabboni I, Dormi A, Corinaldesi E, Lami F, Cicero C, Tchana B, Francavilla R, Sprocati M, Bigucci B, Balsamo C, Valin PS, Di Fazzio G, Iughetti L, Valletta E, Marchetti F, Donti A, Lanari M.
    Clin Rheumatol; 2021 Apr 26; 40(4):1507-1514. PubMed ID: 32936425
    [Abstract] [Full Text] [Related]

  • 33. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age.
    Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, Son C, Lee J.
    Eur J Pediatr; 2009 Nov 26; 168(11):1315-21. PubMed ID: 19159953
    [Abstract] [Full Text] [Related]

  • 34. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
    Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
    Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
    [Abstract] [Full Text] [Related]

  • 35. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
    Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
    [Abstract] [Full Text] [Related]

  • 36. Clinical Presentation and Outcomes of Kawasaki Disease in Children from Latin America: A Multicenter Observational Study from the REKAMLATINA Network.
    Narayan HK, Lizcano A, Lam-Hine T, Ulloa-Gutierrez R, Bainto EV, Garrido-García LM, Estripeaut D, Del Aguila O, Gómez V, Faugier-Fuentes E, Miño-León G, Beltrán S, Cofré F, Chacon-Cruz E, Saltigeral-Simental P, Martínez-Medina L, Dueñas L, Luciani K, Rodríguez-Quiroz FJ, Camacho Moreno G, Viviani T, Alvarez-Olmos MI, Marques HHS, López-Medina E, Pirez MC, Tremoulet AH, Kawasaki Disease REKAMLATINA Network Study Group.
    J Pediatr; 2023 Dec 21; 263():113346. PubMed ID: 36775190
    [Abstract] [Full Text] [Related]

  • 37. Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.
    Tang Y, Yan W, Sun L, Xu Q, Ding Y, Lv H.
    Clin Rheumatol; 2018 Jul 21; 37(7):1945-1951. PubMed ID: 29330741
    [Abstract] [Full Text] [Related]

  • 38. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 21; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 39. Clinical characteristics of Kawasaki disease in Polish children: A retrospective study.
    Smorczewska-Kiljan A, Marszał M, Friedman-Gruszczyńska J, Wieteska-Klimczak A, Książyk J, Jaworski M, Buda P.
    Kardiol Pol; 2022 Nov 21; 80(6):657-663. PubMed ID: 35380006
    [Abstract] [Full Text] [Related]

  • 40. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA, Corydon KE, Shulman ST.
    J Pediatr; 1995 Apr 21; 126(4):524-9. PubMed ID: 7699529
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.